SciELO - Scientific Electronic Library Online

vol.26 número3Propiedades psicométricas de la escala de experiencias de recuperación en trabajadores dependientes peruanosRespuesta a la carta a la editora de “Comentario al Estudio de reactogenicidad de la vacuna ARNm de COVID-19” índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Archivos de Prevención de Riesgos Laborales

versión On-line ISSN 1578-2549

Arch Prev Riesgos Labor vol.26 no.3 Barcelona jul./sep. 2023  Epub 27-Nov-2023 

Letters to the Editor

Comment on "Reactogenicity study of mRNA COVID-19 vaccine"

Amnuay Kleebayoon1, Viroj Wiwanitkit2   

2Adjunct professor, Chandigarh University, Punjab, India

Adjunct professor, Joesph Ayobabalola University, Ikeji-Arakeji, Nigeria

Dear Editor, we would like to share ideas on the publication “Reactogenicity Study of mRNA Vaccines Against COVID-191.” Inglés Torruella et al. compare the reactogenicity of two types of mRNA vaccines against COVID-19, Commirnaty® (Pfizer) and Spikevax® (Moderna), in a healthcare population1. According to Inglés Torruella et al., the greater reactogenicity and its consequences for the first and second doses of the Spikevax® vaccine compared to Comirnaty®, and for the second dose compared to the first dose of both vaccines, provides useful knowledge for planning COVID-19 vaccination campaigns in healthcare settings1.

A variety of factors need to be looked at in order to fully understand the results. It is impossible to draw a relationship between asymptomatic COVID-19 and the lack of symptoms without the required laboratory investigations. Without extensive laboratory testing, asymptomatic COVID-19 and the lack of clinical symptoms could be incorrectly diagnosed. A silent COVID-19 must be ruled out if neither the most recent clinical signals nor the most recent clinical markers are present2. Additionally, genetic variations appear to affect how certain individuals' immune systems react to COVID-193. Before the findings can be verified, more clinical study will be needed.


1. Inglés Torruella J, Gil Soto RM, Sabaté Aguila E, García Grau M, Pons Boronat N, Rubio Civit A, Bandera Baez M, Moreno Martin G. Reactogenicity Study of mRNA Vaccines Against COVID-19. Arch Prev Riesgos Labor. 2023;26(2):106-126. doi: 10.12961/aprl.2022.26.02.02. [ Links ]

2. Joob B, Wiwanitkit V. Letter to the Editor: Coronavirus Disease 2019 (COVID-19), Infectivity, and the Incubation Period. J Prev Med Public Health. 2020;53(2):70. [ Links ]

3. Ciuciulkaite I, Möhlendick B, Thümmler L, Fisenkci N, Elsner C, Dittmer U, Siffert W, Lindemann M. GNB3 c.825cT polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine. Front Genet. 2022;13:932043. [ Links ]


Private Academic Consultant, Samraong, Cambodia.

Creative Commons License This is an open-access article distributed under the terms of the Creative Commons Attribution License